Myozyme was first to market in 2006 for infantile-onset Pompe, with Lumizyme reaching the market four years later to treat late-onset Pompe in children aged over eight.

The company made around $1.3 billion in sales of Myozyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa) – which are both enzyme replacement therapies (ERTs) – in 2022.